| First Author | Girnun GD | Year | 2007 |
| Journal | Cancer Cell | Volume | 11 |
| Issue | 5 | Pages | 395-406 |
| PubMed ID | 17482130 | Mgi Jnum | J:121309 |
| Mgi Id | MGI:3709786 | Doi | 10.1016/j.ccr.2007.02.025 |
| Citation | Girnun GD, et al. (2007) Synergy between PPARgamma Ligands and Platinum-Based Drugs in Cancer. Cancer Cell 11(5):395-406 |
| abstractText | PPARgamma is a member of the nuclear receptor family for which agonist ligands have antigrowth effects. However, clinical studies using PPARgamma ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARgamma activation with chemotherapeutic agents in current use for specific cancers. We observed a striking synergy between rosiglitazone and platinum-based drugs in several different cancers both in vitro and using transplantable and chemically induced 'spontaneous' tumor models. The effect appears to be due in part to PPARgamma-mediated downregulation of metallothioneins, proteins that have been shown to be involved in resistance to platinum-based therapy. These data strongly suggest combining PPARgamma agonists and platinum-based drugs for the treatment of certain human cancers. |
